The estimated Net Worth of Michael Robert Martin is at least $6.46 Milion dollars as of 7 November 2022. Mr. Martin owns over 30,000 units of Aurinia Pharmaceuticals Inc stock worth over $584,513 and over the last 4 years he sold AUPH stock worth over $5,350,361. In addition, he makes $526,116 as Chief Operating Officer at Aurinia Pharmaceuticals Inc.
Sign up
Mr. Martin AUPH stock SEC Form 4 insiders trading
Michael has made over 13 trades of the Aurinia Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 30,000 units of AUPH stock worth $154,800 on 7 November 2022.
The largest trade he's ever made was selling 150,000 units of Aurinia Pharmaceuticals Inc stock on 9 November 2021 worth over $4,537,500. On average, Michael trades about 40,704 units every 39 days since 2021. As of 7 November 2022 he still owns at least 89,512 units of Aurinia Pharmaceuticals Inc stock.
You can see the complete history of Mr. Martin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Martin biography
Michael R. Martin serves as Chief Operating Officer of the Company. Michael Martin is currently COO of Aurinia Pharmaceuticals Inc. In this role he oversees all Business Development, Licensing and Partner Management activities along with overall management of the Company's intellectual property portfolio. Additionally, Michael is responsible for the executive leadership of Aurinia's ocular program. Michael was formerly CEO, director and co-founder of the privately held Aurinia Pharmaceuticals Inc., which merged in 2013 with the former Isotechnika Pharma Inc. Michael is a biotech/pharmaceutical executive with over 20 years of industry experience. Michael joined Aurinia from Vifor Pharma where he held the position of Director, Global Business Development & Licensing. Prior to Vifor, Michael was a key member of the business development team that saw Aspreva sold to Galenica for US$915M. Upon joining Aspreva in 2004, Michael initiated the strategic launch planning process for CellCept® in “less-common” autoimmune diseases. These included such indications as pemphigus vulgaris, myasthenia gravis, and lupus nephritis
What is the salary of Michael Martin?
As the Chief Operating Officer of Aurinia Pharmaceuticals Inc, the total compensation of Michael Martin at Aurinia Pharmaceuticals Inc is $526,116. There are 9 executives at Aurinia Pharmaceuticals Inc getting paid more, with Peter Greenleaf having the highest compensation of $1,678,600.
What's Michael Martin's mailing address?
Michael's mailing address filed with the SEC is #1203-4464 MARKHAM STREET, , VICTORIA, A1, V8Z7X8.
Insiders trading at Aurinia Pharmaceuticals Inc
Over the last 4 years, insiders at Aurinia Pharmaceuticals Inc have traded over $22,019,765 worth of Aurinia Pharmaceuticals Inc stock and bought 107,125 units worth $893,295 . The most active insiders traders include Timothy P Walbert, Michael R Hayden oraz Michael Robert Martin. On average, Aurinia Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $193,451. The most recent stock trade was executed by Scott Michael Habig on 6 August 2024, trading 18,249 units of AUPH stock currently worth $96,902.
What does Aurinia Pharmaceuticals Inc do?
aurinia pharmaceuticals is a biotechnology company located in 5120-75 street, edmonton, canada.
What does Aurinia Pharmaceuticals Inc's logo look like?
Complete history of Mr. Martin stock trades at Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc executives and stock owners
Aurinia Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Peter Greenleaf,
President, Chief Executive Officer, Director -
Peter S. Greenleaf M.B.A.,
Pres, CEO & Director -
Maxwell Donley,
Executive Vice President, Internal Operations & Strategy -
Neil Solomons,
Chief Marketing Officer -
Massimiliano Colao,
Chief Commercial Officer -
Robert Huizinga,
Executive Vice President - Corporate Development -
Matthew Maxwell Donley M.B.A.,
Exec. VP of Operations & Strategy -
Joseph M. Miller CPA,
Chief Financial Officer -
Dennis Bourgeault,
Chief Financial Officer -
Michael Martin,
Chief Operating Officer -
Daniel Billen,
Director -
George Milne,
Independent Chairman of the Board -
Michael Hayden,
Independent Director -
Stephen P. Robertson,
Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer -
Joseph Hagan,
Independent Director -
David Jayne,
Independent Director -
R. Hector MacKay-Dunn,
Director -
Jill Leversage,
Independent Director -
Stephen Robertson,
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary -
Timothy Walbert,
Independent Director -
Max Colao,
Chief Commercial Officer -
Tim Hermes,
Vice President of Market Access -
Cara Felish,
Vice President of Commercial Operations -
Chris Hays,
Vice President of Marketing -
Fran Lynch,
Vice President of Sales -
Glenn Schulman,
Senior Vice President - Corporate Communications and Investor Relations -
Michael R. Martin,
Chief Bus. Officer -
Dr. Robert B. Huizinga M.Sc., Ph.D., R.N., RN NNC, MSc(Epi), CNeph(C),
Exec. VP of Research -
Scott Michael Habig,
Chief Commercial Officer -
Volker Knappertz,
EVP, Research and Development -
Joseph M Miller,
Chief Financial Officer -
Brinda Balakrishnan,
Director -
Robert T Foster,
Director -
Massimilano Colao,
Chief Commercial Officer -
Jeffrey Allen Bailey,
Director -
Karen L. Smith,
Director